News and Announcements
Virtual Content Group Continues Series-A and Finishes FY17 Above Target
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
FY17 EOFY Highlights:
- VCG announces its first investors and continues to raise the Series A from Australian, Asian and European investors.
- As the company finishes FY17 above target, VCG wins more awards including the prestigious “German TV Oscar” Grimme Preis for a VR co-production with a broadcaster and several Lumiere awards from the International VR Society.
- The German arm of VCG was also the exclusive VR partner at the world’s largest film festival, Berlinale earlier this year.
- The group’s production teams have not only filmed on 5 continents but have also live-streamed 360 degree videos from Europe’s largest music festival and many other sports and music events.
- VCG has announced a slate of co-productions with international partners and for the first time VCG is also working on advanced photogrammetry and Augmented Reality projects further cementing the technological leadership in the space.
- In France, the company signed a multi-year contract with the Government and has signed NDAs with several large media companies to supply Virtual Reality content.
- VCG controls one of the largest content catalogs in the industry. The company works with global customers such as Deutsche Telekom, BMW, Hugo Boss, DoCoMo, Hulu, Volkswagen, and many more.
- In 2017 VCG’s founders have given workshops and presentations in Las Vegas, Cannes, Berlin, Tokyo, Shanghai, Singapore.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
